China
China's Avistone Pharmaceuticals raises $200m
Avistone Pharmaceuticals, a Beijing biotech company focused on precision oncology therapeutics has raised more than $200 million in a Series A funding round led by Vivo Capital.
Biotech player CANbridge drops on debut after $87m HK IPO
CANbridge Pharmaceuticals, a Beijing-based drug developer that focuses on treatments for cancer and rare diseases, lost 27% in value on its Hong Kong trading debut following a HK$685.1 million ($87.8 million) IPO.
China’s ABclonal Technology raises $189m
Chinese life science research and diagnostic reagents provider ABclonal Technology has raised a RMB1.2 billion ($189 million) Series D round featuring Sequoia Capital China.
L Catterton backs China-based Amazon vendor aggregator
Nebula Brands, a China-based aggregator of Amazon vendors, has raised $50 million in Series B funding led by L Catterton Asia.
HarbourVest hires Allianz executive for China institutional busines
HarbourVest Partners has recruited Cicely Sun from Allianz Global Investors as a managing director and co-head of its Beijing office.
China's SenseTime plans pared back Hong Kong IPO
Chinese artificial intelligence (AI) technology developer SenseTime is looking to raise up to HK$5.99 billion in a Hong Kong IPO that is considerably smaller than originally envisaged.
Fund focus: Lightspeed bets on green-tech
Green-tech is the latest big idea being championed by Lightspeed China Partners. It has inspired a change in the firm’s name and it will underpin deployment of the new $920 million fund
Deal focus: Gaussian serves China’s aged
With its globally competitive technology and low costs, Gaussian Robotics has become a dominant force in the cleaning robot segment. SoftBank Vision Fund is the latest addition to its cap table
Asia exits: Pass the parcel
Sponsor-to-sponsor exits are set to reach a record high in Asia this year as private equity firms increase velocity of deployment and some strategics remain in a pandemic-induced funk
China surgical robotics player RainMed raises $100m
Ping An Capital has led a Series D round of approximately $100 million for RainMed Medical, a China-based surgical robotics business. Other investors include Seresia Asset Management and Lighthouse Canton.
KKR promotes Chris Sun to partner
Chris Sun (pictured), a managing director at KKR who focuses on investments in China’s consumer sector, has been promoted to partner.
China 3D printing start-up WeNext raises $55m
Temasek Holdings, Cathay Capital Private Equity, and Haochen Capital have led a $55 million Series B round for WeNext Technology, a China-based 3D printing specialist.
China's Didi to delist in New York
China ride-hailing platform Didi, which has traded poorly ever since being targeted by regulators in the wake of its IPO in June, plans to delist from the New York Stock Exchange and relist in Hong Kong.
Wise Road buys semiconductor assets from Taiwan's ASE
Wise Road Capital, a China-based private equity firm that focuses on high-tech investments, has agreed to buy a package of assets from Taiwan-listed semiconductor business ASE Technology Holding for $1.46 billion.
China cleantech: Policy tailwinds
Private equity investment in China cleantech and renewables is at record levels, spurred by robust government support for the industry and a recognition that this time the boom might be sustainable
Lightspeed China closes US dollar fund at $920m
Lightspeed China Partners has closed its latest US dollar-denominated fund at $920 million. It is the largest fund raised by the firm and brings assets under management to $3 billion.
China procurement services start-up raises $102m
Chinese procurement management platform Going-Link, also known as Zhenyun, has raised a RMB650 million ($102 million) Series C round led by Meituan-backed DragonBall Capital.
Vision Fund joins $300m round for China vaccine developer
SoftBank Vision Fund 2 and 5Y Capital have led a $300 million Series C extension for Suzhou Abogen Biosciences, a Chinese vaccine developer focused on mRNA products, including one for COVID-19.
DCP leads $235m round for China's Datong Insurance
DCP Capital Partners has become the largest institutional shareholder in Datong Insurance Service, one of China’s leading insurance brokerages, after leading a RMB1.5 billion ($235 million) round.
Legend hits first close on healthcare fund, launches TMT vehicle
Legend Capital has reached a first close of $177 million on its third US dollar-denominated China healthcare fund. It is one of five vehicles the GP has in the market, including its recently launched ninth flagship technology, media, and telecom (TMT)...
Qiming leads $40m round for Allorion Therapeutics
China and US-based precision medicine company Allorion Therapeutics has raised a $40 million Series A round led by Qiming Venture Partners.
Secondaries supply-demand mismatch most extreme in Asia - AVCJ Forum
There is not enough capital in Asia to address the number of secondary opportunities – mirroring the situation globally – with investors claiming to have more transaction choices than ever before.
China GPU chip designer secures $313m Series A
Moore Threads, a Chinese chip designer established 13 months ago by a team from Nvidia, has closed Series A at RMB2 billion ($313 million) led by Shanghai Guosheng Capital, 5Y Capital, and a BOC International fund.